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Abstract
MicroRNAs are small regulatory RNAs that post-transcriptionally control gene expression. 
Reduced expression of DICER, the enzyme involved in microRNA processing, is frequently 
observed in cancer and is associated with poor clinical outcome in various malignancies. Yet the 
underlying mechanisms are not well understood. Here, we identify tumor hypoxia as a regulator of 
DICER expression in large cohorts of breast cancer patients. We show that DICER expression is 
suppressed by hypoxia through an epigenetic mechanism that involves inhibition of oxygen-
dependent H3K27me3 demethylases KDM6A/B and results in silencing of the DICER promoter. 
Subsequently, reduced miRNA processing leads to derepression of the miR-200 target ZEB1, 
stimulates the epithelial to mesenchymal transition and ultimately results in the acquisition of stem 
cell phenotypes in human mammary epithelial cells. Our study uncovers a previously unknown 
relationship between oxygen-sensitive epigenetic regulators, miRNA biogenesis and tumor stem 
cell phenotypes that may underlie poor outcome in breast cancer.
Cancer mortality is largely attributable to distant metastasis. The mechanisms underlying the 
metastatic process are complex and are part of a series of events that ultimately result in the 
formation of macroscopic metastasis in distant organs from cells with tumor initiating or 
‘stem cell’ properties1. Acquisition of stem cell and metastatic traits that enable this process, 
and the conditions in tumors that stimulate it, are poorly understood. However, many recent 
studies indicate that some tumor cells are able to transition from an epithelial to 
mesenchymal phenotype through a process similar to that which occurs in development 
(EMT). Acquisition of the mesenchymal phenotype is associated with both increased tumor 
initiating properties and the ability to form metastases in experimental models. However, in 
tumors this process requires some degree of plasticity, as formation of a tumor at a 
secondary metastatic site requires transition back to the epithelial cell state (mesenchymal to 
epithelial transition).
miRNAs are small regulatory RNAs that play an important role in normal development and 
in disease by regulating the expression of a vast number of target mRNAs2. miRNA 
biogenesis begins with transcription of long primary miRNAs (pri-miRNA) containing one 
or more hairpin structures that are processed by the nuclear endonuclease DROSHA, 
generating a 70-nucleotide stem loop known as the precursor miRNA (pre-miRNA). The 
pre-miRNA is exported to the cytoplasm by XPO5, and cleaved by DICER in a complex 
with TRBP2 to generate a ~22-nucleotide mature miRNA duplex. One strand is loaded into 
the RNA-induced silencing complex (RISC), which controls gene expression through 
sequence-specific interactions with target mRNAs causing their degradation or translational 
repression3. Several members of this miRNA biogenesis pathway have been identified as 
haplo-insufficient tumor suppressors, including DICER itself, XPO5, and 
TRBP24, 5, 6, 7, 8, 9, 10. Using a variety of mouse models, these studies indicate that partial 
suppression of microRNA biogenesis is sufficient to accelerate tumor development. Loss of 
one DICER allele in mouse models, results in a reduction in overall levels of mature miRNA 
and increased lung and soft tissue sarcomas4, 5. These studies extend earlier clinical findings 
demonstrating that miRNA levels are frequently reduced in tumors6. It is not clear how a 
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reduction in miRNA biogenesis promotes cancer, and whether loss of one or more specific 
miRNAs underlies this effect. However, miRNA has been hypothesized to confer 
‘robustness’ to biological processes including stabilizing differentiated cell states 11. In 
patients, low levels of DICER in breast, ovarian, and other cancers are associated with 
aggressive, invasive disease, distant recurrence, and poor overall survival12, 13, 14. In several 
model systems, DICER repression has also been shown to stimulate metastasis7, 10.
In addition to monoallelic loss in cancer5, several mechanisms have been described as 
potential regulators of DICER including the transcription factors MITF15 and Tap6310, and 
miR-103/1077. DICER expression has also been reported to be inhibited by hypoxia through 
an unknown mechanism16. Hypoxia is a common feature of tumors strongly associated with 
poor prognosis in multiple sites including breast cancer17, 18, 19. Clinical studies show a 
strong association between hypoxia and distant metastasis or relapse19, 20, 21, 22, 23, 24. 
Laboratory data support a direct role for hypoxia in driving metastasis, including in vivo 
studies with cell line derived25, 26, and more recently, patient-derived xenografts grown in 
the orthotopic site. Hypoxia has been suggested to promote stemness in both normal tissues 
and tumors27, 28, 29, 30, 31, 32. However, the mechanisms driving this aggressive phenotype 
are poorly understood.
In this study we have identified a new mechanism linking hypoxia, reduced miRNA 
biogenesis and acquisition of phenotypes associated with poor outcome. We show that 
tumor hypoxia is associated with reduced DICER expression in large cohorts of breast 
cancer patients and identify an epigenetic mechanism that suppresses DICER transcription 
through inhibition of oxygen-dependent H3K27me3 demethylases KDM6A/B. In breast 
cancer, reduced expression of DICER leads to a selective decrease in processing of the 
miR-200 family and consequently to derepression of ZEB1 and activation of the EMT and 
associated stem cell phenotypes.
Results
Reduced DICER expression in hypoxic human breast cancers
Both experimental and clinical data have demonstrated a strong correlation between hypoxia 
and more aggressive disease, including phenotypes recently linked to DICER suppression, 
such as stemness33 and metastasis18, 25. We therefore examined the association between 
DICER expression, DICER copy number and hypoxia in breast cancer. We stratified breast 
cancer patients from two datasets (METABRIC34 and TCGA35) having normal DICER copy 
number by the amount of hypoxia as determined using the validated Winter hypoxia 
signature36 (Fig. 1a and Supplementary Fig. 1a). The median RNA expression of 99 hypoxia 
associated genes in the Winter signature is an independent prognostic factor in head and 
neck squamous cell carcinoma (HNSCC) and breast cancer series. In both datasets, patients 
with the largest hypoxic fraction exhibited the lowest DICER mRNA expression (Fig. 1a 
and Supplementary Fig. 1a). A significant inverse correlation between hypoxia and DICER 
expression was found for the TCGA, METABRIC, Harris, and 14 out of 18 smaller breast 
cancer gene expression studies (Fig. 1b and Supplementary Table 1). A pooled dataset, 
consisting of 19 studies with long-term clinical follow-up, also demonstrated a highly 
significant (p= 5.80 × 10−13) inverse correlation between DICER and hypoxia. Interestingly, 
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in both the pooled and METABRIC datasets, low levels of DICER and high levels of 
hypoxia were associated with poor outcome (Fig. 1c and Supplementary Figs. 2 and 3). 
Notably, the reduction in DICER expression in the most hypoxic quartile was reduced to 
levels similar to that in ∼ 5% of tumors that had monoallelic loss of DICER. These data 
suggest that hypoxia is a key contributor to DICER expression, and responsible for reduced 
DICER levels in significantly more patients than genetic loss. We confirmed that hypoxia 
suppresses DICER at both the mRNA and protein level in a panel of breast cancer (MCF7, 
MDA-MB-468, MDA-MB-231, SUM149, HCC1954), normal (MCF10A) or transformed 
(HMLER) mammary epithelial cell lines after exposure to oxygen levels commonly found in 
human tumors (<0.02 to 1.0% O2) (Fig. 1d-f and Supplementary Fig. 4). Hypoxic 
suppression varied from 26 to 74% at the mRNA level and 16 to 84% at the protein level 
over a period of 24 to 48 hours of hypoxia. DICER repression in hypoxia was not associated 
with any particular breast cancer subtype in either the cell lines or in the breast cancer 
clinical datasets (Supplementary Figs. 2, 3 and Supplementary Table 1).
In addition to monoallelic loss in cancer, several mechanisms have been implicated in 
DICER regulation. These include the transcription factors MITF15 and Tap6310, which 
induce DICER, miR-103/107, which repress DICER7, and a Von Hippel-Lindau dependent 
mechanism affecting DICER protein stability16. We examined each of these and found that 
none could explain suppression of DICER by hypoxia in breast cancer. Reporter constructs 
containing 2.5kb of the DICER promoter (with or without mutations in the MITF E-Box 
elements) showed no regulation by hypoxia (Supplementary Fig. 5a, 5b). Similarly, no 
increase in miR-103/107, and no decrease in DICER transcript or protein stability were 
observed during hypoxia (Supplementary Fig. 5c-f). We also observed no significant 
difference in DICER repression in cell lines isogenic for VHL (Supplementary Fig. 5g). 
Importantly, MITF, Tap63, and miR-103/107 also showed weak or no correlation with 
DICER expression in breast cancer patients in the TCGA and METABRIC datasets 
(Supplementary Fig. 1b-h).
DICER is epigenetically regulated during hypoxia
The lack of regulation of the DICER reporter construct (Supplementary Fig. 5a, 5b) during 
hypoxia was surprising. To directly test if transcription of the endogenous DICER locus was 
affected we measured changes in de novo transcription during hypoxia by pulse-labeling 
RNA. These experiments demonstrated that DICER transcription decreased 40 to 50% 
during hypoxia (Fig. 2a), whereas the HIF-1 target gene carbonic anhydrase-9 (CA9) 
increased 20-fold (Supplementary Fig. 7a). Transcriptional suppression of DICER was not 
dependent on known hypoxia response pathways, including either the HIF (hypoxia 
inducible factor) pathway (as reported previously16) or the PERK/ATF4 arm of the unfolded 
protein response (Supplementary Fig. 6a-e). DICER repression occurred normally in both 
HIF1α knockout cells and in multiple lines where HIF1α was depleted by RNA interference 
(Supplementary Fig. 6a-c). Additionally, hypoxic down-regulation of DICER did not affect 
HIF regulation in breast cancer cell lines, which has been previously reported in other cell 
types16 (Supplementary Fig. 6f).
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Although HIF1 was not required for DICER suppression during hypoxia, we found that 
agents that stabilize HIF by inhibiting the HIF prolyl-hydroxylases (EGLN1/2/3) did cause 
DICER suppression. DFO, CoCl2 and DMOG at concentrations sufficient to activate 
transcription of HIF target genes (e.g. CA9 – Supplementary Fig. 7b) all resulted in a 
significant reduction in DICER at the mRNA and protein level (Fig. 2b, 2d). DFO and 
CoCl2 stabilize HIF by chelating or competing with iron [Fe(II)] whereas DMOG does so by 
competitive inhibition of 2-oxogluterate, which in addition to oxygen, are required co-
factors for the HIF prolyl-hydroxylases that mediate HIF stability. However, like hypoxia, 
treatment with DFO, CoCl2 and DMOG also caused DICER repression in HIF1α knockout 
cells (Fig. 2c).
Since hypoxia, DFO, CoCl2 and DMOG all influenced DICER expression in a HIF1α 
independent manner, we hypothesized that DICER was regulated through inhibition of 
alternative iron, oxygen, and 2-oxogluterate dependent enzymes, such as the Jumonji-
domain (JMJD) containing hydroxylases KDM6A and KDM6B37 that regulate epigenetic 
silencing through removal of repressive histone 3 lysine 27 trimethylation (H3K27me3) 
marks38. Indeed, inhibition of all three required cofactors of the KDM6A/B enzymes by 
hypoxia, DFO, CoCl2 and DMOG resulted in an increase in total H3K27me3 in multiple cell 
types (Fig. 2d and Supplementary Fig. 7c). More importantly, H3K27me3 chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) demonstrated that hypoxic 
exposure for as short as 8 hours led to an increase in repressive H3K27me3 marks in the 
DICER promoter region (Supplementary Fig. 7d). Enrichment in H3K27me3 at the DICER 
promoter during hypoxia was confirmed using conventional ChIP-qPCR in MCF7 (8-fold 
enrichment vs. hypoxic IgG control) and HMLER (5-fold enrichment vs. hypoxic IgG 
control) cell lines (Fig. 2e). In both cell lines this translated into an approximate doubling of 
H3K27me3 as compared to levels under normoxia. Furthermore, ChIP-qPCR analysis using 
specific antibodies against the H3K27 methyltransferase EZH2 (writer) and the oxygen-
dependent H3K27me3 demethylases KDM6A and KDM6B (erasers) revealed significant 
enrichment over IgG controls at the DICER promoter for each respective enzyme with no 
significant difference in enrichment between normoxic and hypoxic conditions (Fig. 2f). 
Consistent with a role for epigenetic regulation of DICER, knockdown of KDM6A or 
KDM6B resulted in reduced DICER expression (Fig. 2g and Supplementary Fig. 7e-g). 
Similarly, inhibition of KDM6A/B with the inhibitor GSK-J4 at concentrations that 
increased overall levels of H3K27me3 by 1.3 fold, caused a 23% and 50% decrease in 
DICER expression in MCF7 and HMLER cells respectively (Fig. 2h,i and Supplementary 
Fig. 7h, 7i) without affecting HIF activity (Supplementary Fig. 7h). Conversely, knockdown 
of EZH2 resulted in a significant increase in DICER expression and was able to largely 
prevent DICER repression during hypoxia (Fig. 2j and Supplementary Fig. 7j). Similarly, 
inhibition of EZH2 using UNC1999 and GSK343 at levels that caused decreases in global 
H3K27me3 levels by 50-70% (Fig. 2l and Supplementary Fig. 7k) also increased DICER to 
levels comparable with EZH2 knockdown (Fig. 2k and Supplementary Fig. 7l). Together, 
these data indicate that basal expression of DICER is regulated by dynamic and opposing 
activities of KDM6A/B and EZH2, which are both constitutively present at the DICER 
locus, and that suppression of KDM6A/B activity under hypoxia is sufficient to increase 
H3K27me3 in an EZH2 dependent manner and suppress DICER transcription.
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Hypoxia causes a miRNA processing defect
To examine the consequences of DICER suppression, we created MCF7 and HMLER breast 
cancer cell lines with stable knockdown of DICER and assessed changes in levels of mature 
miRNA. Suppression of DICER to ~30% resulted in a widespread reduction in mature 
miRNA for the majority of miRNA species (Fig. 3a, 3b and Supplementary Fig. 8a). 
Hypoxia also led to an analogous impairment in the processing of exogenously introduced 
shRNA (Supplementary Fig. 8b). siRNA and shRNA targeting HIF1α showed similar 
efficiency under aerobic conditions, but under hypoxia HIF1α shRNA, which requires 
DICER processing, was significantly less efficient. Under hypoxia, HIF1α siRNA reduced 
the HIF target gene CA9 by ~50%, whereas HIF1α shRNA failed to prevent CA9 induction.
Sensitivity to DICER knockdown varied amongst different miRNA and the 5 members of 
the miR-200 family (miR-200a, miR-200b, miR-429, miR-200c, and miR-141) were 
amongst the most strongly repressed in both lines (Fig. 3b and Supplementary Fig. 8a). 
Similarly, the miR-200a/b/429 cluster was amongst the most strongly repressed miRNAs in 
response to hypoxia (Fig. 3c). We confirmed that both hypoxia and DICER knockdown led 
to a substantial defect in the processing of miR-200 family precursors (pri-miRNAs) into 
mature miRNAs. The ratio of mature to pri-miRNA, an indicator of DICER activity, 
dropped substantially in response to both DICER knockdown and hypoxia in MCF7, 
HMLER, and SUM149 cells (Fig. 3d-f and Supplementary Fig. 8c). Furthermore, the 
reduction in DICER caused by inhibition of KDM6A/B using GSK-J4 also resulted in a 
decrease in miR-200a/b/429 processing similar to that during hypoxia or DICER knockdown 
(Fig. 3d). Conversely, inhibition of EZH2 using UNC1999, which increased DICER 
expression, increased miR-200a/b/429 processing (Fig. 3d). Importantly, transient 
overexpression of DICER during hypoxia increased miR-200a/b/429 processing to near 
basal levels, demonstrating that these effects on miRNA processing under hypoxia are due 
to its effects on DICER (Fig. 3d, 3f and Supplementary Fig. 8d).
Despite the defect in miRNA processing caused by DICER repression, some mature 
miRNAs increased during hypoxia, including the widely reported hypoxia inducible 
miR-210. However, in this case the increase is due entirely to a transcriptional effect 
(Supplementary Fig. 8e, 8f and Fig. 3g, 3h). The processing of miR-210 mediated by 
DICER is reduced under hypoxia but this effect is smaller than the overall transcriptional 
increase resulting in increased mature levels of the miRNA.
Hypoxia stimulates EMT and CSC associated properties
The miR-200 family is implicated in regulation of the ZEB1 and ZEB2 transcription factors, 
which repress E-cadherin and stimulate the EMT39. DICER knockdown has previously been 
implicated in promoting the EMT and metastasis through the miR-200 family7, and 
miR-200b repression and ZEB1 induction during hypoxia has been reported40, 41. We 
hypothesized that DICER suppression during hypoxia may similarly regulate the EMT and 
perhaps underlie the known association of tumor hypoxia with metastasis, stemness and 
aggressive disease. Indeed, DICER repression in response to hypoxia or knockdown resulted 
in enhanced expression of ZEB1, loss of epithelial marker expression (E-cadherin) and 
increased expression of mesenchymal markers (N-cadherin and Vimentin) (Fig. 4a-c). The 
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transcription factor TWIST, previously implicated in hypoxia-induced EMT and 
metastasis42 remained unchanged, as did the transcription factor SNAIL (Supplementary 
Fig. 9a, 9b). The hypoxia and DICER knockdown induced EMT is mechanistically distinct 
from the classical EMT inducer TGFβ1, which was associated with increased expression of 
TWIST and SNAIL, but caused no change in DICER expression or miRNA biogenesis 
(Supplementary Fig. 9c-e).
In breast cancer, the EMT has been linked to acquisition of stem cell phenotypes, including 
expression of cell surface antigens associated with human breast stem cells (CD44high 
CD24low), increased mammosphere formation, and increased tumor initiation 
capacity43, 44, 45. In HMLER cells, hypoxic exposure led to an increase in the frequency of 
CD44high CD24low cells from 11.5% to 73.7% (Fig. 4d, 4e), comparable to levels observed 
following exposure to TGFβ1 (Supplementary Fig. 9e) or reported following forced 
exposure of SNAIL or TWIST43. A similar increase in the fraction of CD44highCD24low 
cells occurred following DICER knockdown alone (76.6% and 81.5% vs. 14.1%) (Fig. 4d, 
4e). Both hypoxic exposure and DICER knockdown resulted in a greater than 5-fold 
increase in mammosphere formation similar to that observed following TGFβ1 exposure 
(Fig. 4f). Importantly, hypoxia is similarly able to influence H3K27me3, DICER, EMT, and 
stem cell phenotypes in vivo. We established HMLER xenografts and examined the spatial 
relationship between hypoxia, H3K27me3, and CD44 using multi-fluorescence 
immunohistochemistry. As shown in Fig. 4g and 4h, tumor hypoxia in vivo (as assessed by 
EF5) is strongly associated with increased expression of the stem cell marker CD44 (Fig. 4g, 
4h). Hypoxic tumor areas also show increased overall levels of H3K27me3, with discernable 
gradients in expression away from hypoxic areas (Fig. 4i). Furthermore, we assessed 
DICER, ZEB1, and E-cadherin expression in vivo using a panel of breast cancer xenografts 
and found that DICER and E-cadherin were inversely correlated with the endogenous 
hypoxia marker CA9 whereas ZEB1 showed a positive correlation with CA9 
(Supplementary Fig. 9f).
Finally, we tested directly if hypoxia and DICER knockdown induced EMT and acquisition 
of stem cell phenotypes is dependent on loss of mature miR-200 levels. DICER 
overexpression during hypoxia, which rescued the defect in miR-200 processing (Fig. 3d), 
also prevented increased expression of ZEB1 (Supplementary Fig. 9g). Furthermore, 
overexpression of miR-200b alone, prevented increased expression of ZEB1 and loss of E-
cadherin during hypoxia, without affecting DICER repression and the defect in miRNA 
biogenesis (Fig. 5a, 5b). miR-200b overexpression during hypoxia also prevented the 
increase in the CD44highCD24low population and mammosphere formation (Fig. 5c-e). 
Together, these demonstrate that hypoxic suppression of DICER causes an EMT driven 
acquisition of stem cell properties in breast cancer through a reduction in the biogenesis of 
mature miR-200 family members (Fig. 5f).
Discussion
Our study demonstrates that hypoxia in the tumor microenvironment is a contributor to 
DICER expression and repression of miRNA biogenesis. In large independent cohorts of 
breast cancer patients, the association between hypoxia and DICER is stronger than any 
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previously reported regulator of DICER, and the number of patients affected by this 
mechanism exceeds those harboring monoallelic loss. This analysis also indicates that 
DICER suppression may underlie part of the known association of hypoxia with metastasis 
and poor outcome, although hypoxia remains a better discriminator than DICER in breast 
cancer patients. This is perhaps not surprising given that hypoxia influences other important 
biological processes including angiogenesis, altered metabolism, and chromosomal 
instability. The changes in histone methylation and DICER expression are relatively small 
(~2-fold) in response to hypoxia or inhibition of EZH2 and KDM6A/B. Previous studies 
unambiguously identified DICER as a haploinsufficient tumor suppressor and an important 
driver of tumorigenesis under conditions of less than 50% repression4, 5. Our study is 
consistent with these earlier reports, and demonstrates that relatively small changes in 
DICER expression during hypoxia underlie functional changes in miRNA biogenesis, EMT, 
and properties associated with stemness. Interestingly, Rupaimoole et al. have demonstrated 
that hypoxia causes additional suppression of miRNA biogenesis through silencing of 
DROSHA (in print in the same issue), and that the combined defect in miRNA biogenesis 
resulting from DICER and DROSHA suppression leads to increased metastasis in ovarian 
cancer. The coordinated suppression of these two key enzymes required for miRNA 
biogenesis as well as hypoxia dependent suppression of AGO246 suggests a particularly 
important and broad role for oxygen in the regulation of miRNA levels. The consequences 
of such regulation are likely to be different in specific tissues and cancer types, depending 
upon the expression of different miRNAs. In breast cancer, we show that selective 
sensitivity of the miR-200 family to loss of DICER plays a dominant role in regulation of 
EMT and cancer stem cell phenotypes, which may underlie the known association of 
hypoxia with aggressive disease in breast and other cancer types12, 13, 14, 17, 18.
Previous studies have reported multiple mechanisms of DICER regulation, which can occur 
at the level of transcription through MITF15 and Tap6310, mRNA stability through 
miR-103/107 as well as at the protein level in a VHL dependent manner16. Our study reveals 
that DICER transcription is also regulated dynamically by acquisition or loss of the 
repressive H3K27me3 polycomb mark that is typically associated with gene silencing38. 
This mark is also found on promoters of so-called ‘poised’ genes expressed at low levels in 
embryonic stem cells where it is often associated with co-occurrence of the activating H3K4 
mark47. Several previous studies have indicated that the balance between writing (EZH2) 
and erasing (KDM6A/B) H3K27me3 marks within the genome can play an important role in 
cancer48, 49. This is supported by the finding that EZH2 is frequently overexpressed or 
activated in cancer50, 51, 52, and associated with increased metastasis53. Conversely, the 
H3K27me3 demethylase KDM6A is frequently mutated in human cancers54, 55 and KDM6B 
expression is decreased in subsets of human cancers56, 57. Our study identifies DICER as an 
important integrator of EZH2 methyltransferase and KDM6A/B demethylase activity. We 
showed that EZH2 and KDM6A/B are present at the DICER locus, and that inhibition of 
these enzymes can cause acute changes in the levels of H3K27me3, DICER expression, and 
DICER activity. The hydroxylase activity of KDM6A/B requires molecular oxygen, 2-
oxogluterate, and Fe(II) in order to demethylate H3K27me3. Correspondingly we found that 
hypoxia, or depletion/competition of the other cofactors with DFO, CoCl2 or DMOG all 
suppress DICER. To our knowledge, this is the first such example of a gene whose 
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expression is dynamically regulated at the epigenetic level by the availability of metabolic 
enzymatic co-factors. Since the basal levels of H3K27me3 are influenced by both EZH2 and 
KDM6A/B activities, we expect that additional metabolic cofactors that regulate their 
activity including methyl donation (EZH2) or 2-oxogluterate (KDM6A/B) will similarly 
influence DICER H3K27me3 levels and its expression.
In contrast to genetic alteration of EZH2 and/or KDM6A/B, hypoxia driven changes in the 
epigenetic state of DICER enables transient changes in cell phenotype in response to the 
local tumor microenvironment. In breast cancer, our findings demonstrate that suppression 
of DICER during hypoxia is sufficient to reduce miR-200 levels and enable cells to undergo 
an EMT and acquire stem cell properties. The fact that this occurs at the epigenetic level in 
an EZH2 dependent manner is consistent with a recent report that implicates EZH2 in 
controlling the EMT through epigenetic reprogramming58, but provides a potential 
mechanism for cells to retain plasticity and restore DICER and miR-200 levels when oxygen 
becomes available. Cancer cells need to undergo the reverse process, mesenchymal to 
epithelial transition, to ensure successful colonization and metastatic outgrowth59, 60. We 
speculate that the clinical importance of hypoxia in driving metastasis and poor outcome is 
linked to this ability to transiently influence cell phenotype via DICER expression and 
miRNA biogenesis.
Finally, our results provide new potential therapeutic opportunities for targeting hypoxia and 
its influence on poor outcome in cancer. Hypoxia has been demonstrated to influence patient 
outcome both through its ability to promote metastatic growth of disseminated stem cells, 
and for regrowth of tumors following treatment. Hypoxic cells are intrinsically resistant to 
radiation and other forms of chemotherapy, and small numbers of these cells can ‘re-seed’ 
the tumor, enabling regrowth following therapy. Hypoxic tumor cells also arise as a 
consequence of treatment with anti-angiogenic agents, and can contribute to tumor regrowth 
post therapy61. Consequently, the ability of hypoxic cells to stimulate tumor initiation – 
either in naïve metastases or following therapy of primary tumors, is considered to play a 
large role in treatment outcome. It may be possible to interfere with the epigenetic regulation 
of DICER during hypoxia and/or its influence on the expression of key miRNAs that 
promote these adverse clinical effects. Recent potent, orally available inhibitors of EZH2 
have been reported62, 63, and our results suggest that treatment with these agents induce 
DICER expression. Alternatively, a siRNA and/ or miRNA strategy that does not rely on 
Drosha/Dicer processing and is not compromised within the tumor microenvironment could 
be applied. Effective delivery of siRNA and/or miRNA in vivo has improved remarkably 
and pre-clinical studies have demonstrated the potential of miR-200b delivery in breast, 
ovarian, and other orthotopic models64.
Methods
Data set analyses
Retrieval and processing of breast cancer datasets—Preprocessing of raw mRNA 
abundance datasets was performed in R statistical environment (v2.14.1). Raw affymetrix-
based data (PMIDs: 16273092, 17545524, 16141321, 16280042, 16478745, 18498629, 
17157792, 19421193, 20098429, 20064235, 20490655, 20697068, 18821012, 18593943, 
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15721472, 21501481, 17079448, 21422418 and 21558518) were normalized using RMA 
(robust multi-array average) algorithm65 (R package: affy v1.32.1). ProbeSet annotation to 
Entrez Gene IDs was performed using custom CDFs66 (R packages: hgu133ahsentrezgcdf 
v15.0.0, hgu133bhsentrezgcdf v15.0.0, hgu133plus2hsentrezgcdf v15.0.0, 
hthgu133ahsentrezgcdf v15.0.0, hgu95av2hsentrezgcdf v15.0.0 for affymetrix-based breast 
cancer datasets). The METABRIC breast cancer dataset was preprocessed, summarized and 
quantile-normalized from the raw expression files generated by Illumina BeadStudio (R 
packages: beadarray v2.4.2 and illuminaHuman v3.db_1.12.2). Raw data files were 
downloaded from European genome-phenome archive (EGA) (Study ID: 
EGAS00000000083). Data files of one sample were not available at the time of this 
analysis, and were therefore excluded. All datasets were normalized independently. 
Preprocessed segmented genome copy number aberration (CNA) data from the METABRIC 
cohort was downloaded from EGA. Preprocessed mRNA abundance data from The Cancer 
Genome Atlas (TCGA) were downloaded from cBioPortal for Cancer Genomics of 
Memorial Sloan-Kettering Cancer Center (MSKCC) http://www.cbioportal.org/public-
portal/ on Nov. 6, 2012. Level 4 processed copy number aberration (CNA) data from TCGA 
were downloaded from GISTIC2 from the Broad Institute at http://gdac.broadinstitute.org/
runs/analyses__2012_09_13/reports/cancer/BRCA/copynumber/gistic2/nozzle.html Discrete 
amplification and deletion calls for each sample based on the obtained CNA data were 
tabulated. For both mRNA abundance and CNA data, patient clinical information were 
obtained online from the original publication35.
Calculation of Winter signature scores—For each gene in the Winter signature, each 
patient in a given cohort was assigned an initial score of either +1 or −1 as follows: A 
patient was assigned +1 if her expression of that gene exceeded the median expression of 
that gene in that complete cohort. Otherwise, the patient was assigned −1 for that gene. For 
each patient in a given cohort, the +1’s and −1’s obtained as described above over all genes 
in the Winter signature were summed, and the resulting sum was the Winter signature score 
for that patient in that cohort.
mRNA abundance correlation analysis of Dicer with MITF or TP63—For each of 
the Metabric (Training and Validation datasets combined) and TCGA breast cancer mRNA 
abundance data sets, a scatter plot was generated of the Dicer mRNA abundance against that 
of MITF. Pearson’s product-moment correlation coefficient of the mRNA abundance of the 
two genes was computed and its p-value, based on the two-sided t-test for the Pearson’s 
product-moment correlation, was computed. This analysis was repeated for the correlation 
of Dicer mRNA abundance and TP63 mRNA abundance.
Comparison of Dicer mRNA abundance and Winter signature—For each of the 
Metabric (Training and Validation datasets combined) and TCGA breast cancer data sets, 
only patients with no Dicer copy-number variation and those with monoallelic Dicer loss 
were retained. These retained patients were then divided into five groups as follows: Those 
with monoallelic Dicer loss formed one group, and those with no Dicer copy-number 
variation were ordered by their Winter signature scores and divided into four quarters, with 
the first quarter comprising patients with the lowest Winter signature scores while the fourth 
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represents those with highest Winter signature scores. A strip plot was generated to visualize 
the differences in Dicer mRNA abundance levels among these five groups. The Dicer 
mRNA abundance of patients in each of the four quarters of the group with no Dicer copy-
number variation was compared against the group with monoallelic Dicer loss, by 
computing the p-value based on the Wilcoxon rank sum test.
Comparison of miR-103/107 expression and Winter signature—Analyses were 
carried out in R statistical environment (version 3.0.1) (http://www.r-project.org/). All tests 
were two-sided and considered statistical significant at the 0.05 level. Clinical and miRNA 
expression were downloaded from the Cancer Genome Atlas Project (TCGA) available 
through the associated files of the paper: Comprehensive molecular portraits of human 
breast tumors, Nature, September 27, 2012. https://tcga-data.nci.nih.gov/docs/publications/
brca_2012/. We also downloaded Level 3 (RNASeqV2) genes profiles for Breast Invasive 
Carcinoma from TCGA Data Portal: https://tcga-data.nci.nih.gov/tcga/. A hypoxia score was 
assigned to each TCGA sample based on the Winter hypoxia metagene signature and 
following the previously reported methodology67. The Shapiro-Wilk test was applied to 
verify if the data follows a normal distribution. Accordingly, an analysis of variance test 
with Tukey post-hoc test was applied to assess the relationship between miR-103 and Winter 
hypoxia score, whereas a non-parametric test Kruskal–Wallis test with Nemenyi post-hoc 
test was applied to assess the relationship between miR-107 expression and Winter hypoxia 
score.
Cell culture and treatment—The following cell lines were obtained from ATCC and 
grown according to provided subculturing instructions: MCF7, MDA-MB-468, MDA-
MB-231, T47D, U373, HCT116, Hela, ME180 and SiHa. HCC1954 and SUM149 cell lines 
were provided as a gift from Dr. Benjamin Neel (Princess Margaret Cancer Centre). 
HCC1954 cells were grown in RPMI medium supplemented with 10% FBS and SUM149 
cells were grown in Ham’s F12 medium supplemented with 5% FBS, insulin (5 μg/ml), 
hydrocortisone (1 μg/ml), and 10mM Hepes (pH 7.4). HMLER cells were a gift from Dr. 
Robert Weinberg (MIT) and were grown as previously described68. MCF10A cells were 
provided by Dr. Senthil Muthuswamy (Princess Margaret Cancer Centre) and were grown in 
DMEM/F12 (Gibco BRL) supplemented with 5% donor horse serum, 20 ng/ml EGF, 10 
μg/ml insulin, 1 ng/ml cholera toxin, 100 μg/ml hydrocortisone, 50 μg/ml penicillin and 50 
μg/ml streptomycin. WT and HIF1α−/− MEFs, RCC4 and RCC4+pVHL were grown in 
DMEM medium supplemented with 10% FBS. All cell lines were routinely tested to 
confirm the absence of Mycoplasma. For hypoxic exposure cells were transferred into a 
HypOxygen H35 workstation. The atmosphere in the chamber consisted of 5% H2, 5% CO2, 
the desired % O2, and residual N2. For protein stability experiments, MCF7 cells were 
exposed to 100 μg/ml cycloheximide (Sigma) for 0, 2, 4, or 8 hours of normoxia or 0.2% O2 
hypoxia. For exposure to stress inducing agents, indicated cell lines were grown for 24 hrs in 
250 μM cobalt chloride (CoCl2), 500 μM deferoxamine (DFO) or 500 μM 
dimethyloxalylglycine (DMOG). For inhibition of KDM6A/B activity, MCF7 and HMLER 
cells were grown for 24 hrs in GSK-J4 at indicated concentrations. For inhibition of EZH2 
activity, MCF7 and HMLER cells were grown for 48-72 hrs in UNC1999 or GSK343 at 
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indicated concentrations. For exposure to TGFβ1, HMLER cells were cultured in standard 
growth medium with the addition of 5% FBS and treated with 2.5 ng/ml TGFβ1 for 12 days.
RNA extraction and quantitative RT-PCR—RNA was isolated using TRI reagent 
(Sigma) and samples were reverse transcribed using qScript cDNA SuperMix (Quantas). 
Quantitative real-time PCR was performed on an Eppendorf Realplex2 mastercycler using 
SYBR green (Quantas). Specific primers used are listed in Supplementary Table 2. For 
determination of DICER mRNA half life cells were treated with 5 μg/ml actinomycin D 
(Sigma) for the indicated times. De novo RNA synthesis was measured using the Click-iT 
Nascent RNA Capture Kit (Molecular Probes). Briefly, MCF7 and HMLER cells were pulse 
labeled with 0.2mM 5-ethynyl Uridine for 1 hour during aerobic conditions or 24 hrs 
hypoxia (0.2% O2) after which RNA was isolated as described above. Nascent RNA was 
captured using magnetic streptavidin beads, reverse transcribed and analyzed by quantitative 
real-time PCR. For determination of pri-miRNA and mature miRNA levels the following 
assays from Applied Biosystems were used: pri-miR200a (Hs03303376_pri), pri-miR200b 
(Hs03303027_pri), pri-miR429 (Hs03303727_pri), pri-miR200c (Hs03303157_pri), pri-
miR141 (Hs03303157_pri), pri-miR210 (Hs03302948_pri), hsa-miR200a (000502), hsa-
miR200b (002251), hsa-miR429 (001024), hsa-miR200c (002300), miR141 (002145), hsa-
miR103 (000439), hsa-miR107 (000443), hsa-miR210 (000512), RNU44 (001094), RNU48 
(001006).
Western blot analysis—Cells were washed twice with cold PBS and scraped in 50 mM 
Tris HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS 
supplemented with protease and phosphatase inhibitors (Roche). After centrifugation at 
10,000 g supernatants were boiled in Laemmli buffer for 10 min and proteins were resolved 
by SDS-PAGE. Proteins were subsequently transferred onto PVDF membrane and blocked 
for 1 hour in TBS containing 0.05% Tween 20 (TBS-T) supplemented with 5% skim milk 
powder. Membranes were probed overnight at 4°C with antibodies directed against: DICER 
(1:200, H-212; Santa Cruz Biotechnology), CA9 (1:1000, M75; gift from Dr. Silvia 
Pastorekova), H3K27me3 (1:20000, 07-449; Upstate), H3 (1:5000, D1H2; Cell Signaling 
Technology), E-cadherin (1:1000, Cell Signaling Technology), Vimentin (1:500, clone V9; 
Sigma), β-tubulin (1:20000, Abcam), β-actin (1:20000, Sigma) or eIF4E (1:1000, BD 
Transduction Laboratories). Bound antibodies were visualized using HRP-linked secondary 
antibodies (GE Healthcare) and ECL luminescence (Pierce).
Luciferase reporter assay—A 2.5 kb fragment from the 5′ flanking region of the 
DICER1 gene was previously described15. MCF7 cells were transiently co-transfected with 
the DICER or CA9 promoter69 constructs and pcDNALacZ using Lipofectamine 
(Invitrogen). Transfected cells were subcultured 16 hrs post-transfection, exposed to 
hypoxia and finally harvested 48 hrs after transfection. Luciferase and β-galactosidase 
activity was measured using a commercial kit (Applied Biosystems) and measured on the 
Fluorstar Optima plate reader (BMG Labtech).
Plasmids and viral infections—Knockdown was achieved using lentiviral shRNA 
constructs directed against DICER: TRCN0000004386, TRCN000000439; HIF-1α: 
van den Beucken et al. Page 12
Nat Commun. Author manuscript; available in PMC 2015 April 29.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
TRCN0000003810; KDM6A: TRCN0000107760; KDM6B: TRCN0000236677; GFP as 
control: TRCN0000072181. DICER ORF was cloned into pLenti CMV DEST using 
Gateway LR Clonase II (Invitrogen). PrimiR200b was cloned into pLJM1 as Age1/EcoR1 
fragment. Lentiviral particles were generated by co-transfection of 293T cells with 
packaging plasmids pCMVdR8.74psPAX2 and pMD2.G together with shRNA vector 
pLKO.1 using Lipofectamine 2000. Virus supernatant was harvested 48 and 72 hrs post-
transfection. Cell lines were transduced with lentiviral supernatant in the presence of 8 
μg/ml polybrene. Infected cells were selected for 48 hrs in 2 μg/ml puromycin containing 
media or 7 days in 5 μg/ml blasticidin containing media. Validated short interfering RNA 
(siRNA) duplexes directed against EZH251 AAGACTCTGAATGCAGTTGCT and HIF1α 
CUGAUGACCAGCAACUUGA were ordered from Sigma. Stealth RNAi negative control 
was ordered from Invitrogen (12935-300). For siRNA experiments cells were transfected 72 
hours before analysis with 2 nM siRNA duplex using lipofectamine (Invitrogen).
Chromatin immunoprecipitation (ChIP)—MCF7 and HMLER cells were fixed in 1% 
formaldehyde. Cross-linking was allowed to proceed for 10 min at room temperature and 
stopped by addition of glycine at a final concentration of 0.125 M, followed by an additional 
incubation for 5 min. Fixed cells were washed twice with PBS and harvested in SDS Buffer 
(50 mM Tris at pH 8.1, 0.5% SDS, 100 mM NaCl, 5 mM EDTA), supplemented with 
protease inhibitors (Aprotinin, Antipain and Leupeptin all at 5μg/mL and 1mM PMSF). 
Cells were pelleted by centrifugation, and suspended in IP Buffer (100 mM Tris at pH 8.6, 
100 mM NaCl , 0.3% SDS, 1.7% Triton X-100, and 5 mM EDTA), containing protease 
inhibitors. Cells were disrupted by sonication, yielding genomic DNA fragments with a bulk 
size of 200-500 bp. For each immunoprecipitation, 1 mL of lysate was precleared by 
addition of 35 μL of blocked protein A beads (50% slurry protein A-Sepharose, Amersham; 
0.5 mg/mL fatty acidfree BSA, Sigma; and 0.2 mg/mL herring sperm DNA in TE), followed 
by clarification by centrifugation. 10μl aliquots of precleared suspension were reserved as 
input DNA and kept at 4°C. Samples were immunoprecipitated overnight at 4°C using 1 μg 
of antibodies for either HA as a negative control (sc-805; Santa Cruz), H3K27me3 (07-449; 
Upstate), EZH2 (AC22, Millipore), KDM6A (ab36938, Abcam) or KDM6B (ab85392, 
Abcam). Immune complexes were recovered by adding 40 μL of blocked protein A beads 
and incubated for 4 hrs at 4°C. Beads were washed three times in 1 mL of Mixed Micelle 
Buffer (20 mM Tris at pH 8.1, 150 mM NaCl, 5 mM EDTA, 5% w/v sucrose, 1% Triton 
X-100, and 0.2% SDS), twice in 1mL of Buffer 500 (50 mM HEPES at pH 7.5, 0.1% w/v 
deoxycholic acid, 1% Triton X-100, and 1 mM EDTA), twice in 1mL of LiCl Detergent 
Wash Buffer (10 mM Tris at pH 8.0, 0.5% deoxycholic acid, 0.5% NP-40, 250 mM LiCl, 
and 1 mM EDTA), and once in 1mL of TE. Immuno-complexes were eluted from beads in 
250μL elution buffer (1% SDS; and 0.1M NaHCO3) for 2 hrs at 65°C with continuous 
shaking at 1000 rpm, and after centrifugation supernatants were collected. 250μL elution 
buffer was added to input DNA samples and these were processed in parallel with eluted 
samples. Crosslinks were reversed overnight at 65°C followed by a 2h digestion with 
RNAseA at 37°C and 2h proteinase K (0.2μg/μL) at 55°C. DNA fragments were recovered 
using QIAquick PCR purification columns, according to manufacturers’ instructions. 
Samples were eluted in 75 μL EB buffer and then further 1/5 diluted in TE buffer. The 
immunoprecipitated DNA was quantified by real-time qPCR using SYBR® Green I 
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(Applied Biosystems) and following forward and reverse primers: DICER: 
FCGGTGGGCGTTAAATAAGTG and R-CCCCCATACTGAGATGCTGT. After PCR 
melting curves were acquired to ensure that a single product was amplified in the reaction.
Global miRNA profiling—Total RNA was isolated from cells bearing shDICER G6 and 
pLKO.1 as control or cells exposed to hypoxia and samples were subjected to Nanostring 
analysis using the Nanostring Human v2 miRNA code set at the UHN Microarray Centre. 
miRNAs with counts equal or lower than the negative controls were discarded from the 
analysis. miRNA counts were normalized to housekeeping gene RPLP0 and averaged for 3 
independent experiments.
Fluorescence-activated cell sorting—FACS analysis was performed on a BD FACS 
Calibur (Becton Dickinson) using PE-conjugated anti-CD24 antibody (clone ML5) and 
APC-conjugated anti-CD44 (clone G44-26) (BD bioscience).
Mammosphere culture—Mammosphere culture was performed as previously 
described70 with slight modifications. The mammospheres were cultured for 7-10 days in 
MammoCult media (StemCell Technologies) supplemented with 4 μg/ml heparin (Sigma) 
and 0.5 μg/ml hydrocortisone (Sigma). For sphere formation assays, mammospheres were 
dissociated to single cells with trypsin and 500 dissociated cells were plated in a 96-well 
plate and cultured for 10 days. Mammospheres with diameter >75 μm were counted.
In vivo models—All animal experiments were performed under protocols approved by the 
Ontario Cancer Institute’s Animal Care Committee, according the regulations of the 
Canadian Council on Animal Care. Female NOD-SCID mice at 6-8 weeks old were used to 
inject HMLER cells into the inguinal mammary fat pad (1 × 106 cells in a 1:1 mixture of BD 
Matrigel and media) following anesthetization with isoflurane. One week prior to the 
injection of cells, a 60-day release pellet containing 2 mg 17β-estradiol and 20 mg 
progesterone (Innovative Research of America) was implanted subcutaneously into each 
mouse. At end point, mice were sacrificed, tumors harvested, and OCT embedded for 
immunohistochemical staining and analysis.
Immunohistochemical staining and image analysis—The expression of CD44 and 
EF5 in orthotopic xenografts was investigated as follows: Flash frozen tissue samples were 
embedded in OCT and stored at −80C until sectioned. Sections were thawed at room 
temperature prior to fixation in 2% paraformaldehyde for 20 mins. After washing sections in 
PBS, sections were permeabilized in PBS containing 0.5% Triton X-100 for 15 minutes, 
wash 3×5 mins in PBS-T and then incubated in a primary antibody cocktail of mouse anti-
human CD44 (1:75, BD Pharmingen) and rat anti-mouse CD31 (1:300, BD Pharmingen) or 
anti-human H3K27me3 (1:500, C36B11; Cell Signalling) overnight at room temperature. 
Sections were subsequently washed 3×5 mins in PBS-T followed by incubation in a 
secondary antibody cocktail of goat anti-mouse Alexafluor 488 (1:200, Life Technologies) 
and goat anti-rat Alexafluor 555 (1:200, Life technologies) or goat anti-mouse Alexafluor 
488 (1:200, Life Technologies) for 1 hour at room temperature. After washing in PBS-T, 
sections were incubated in EF5-Cy5 (1:50, provided by Dr. Cameron Koch) for 3 hours at 
room temperature. After washing, sections were finally incubated in a working solution of 
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DAPI for 5 minutes, washed, dried and imaged on a laser scanning microscope (Huron 
Technologies). Images were analyzed using Definiens Tissue Studio software, which allows 
for semi-automatic histology image analysis. Briefly, the software was trained to identify 
viable tumor areas, necrotic areas, tumor stroma, and empty areas within the scanned 
section. A threshold was determined by mean +2SD intensity in the EF5 and CD44 
channels. The average CD44 staining intensity within the tumor area was measured in both 
EF5 negative and positive areas. EF5-positive area above a background threshold was 
obtained from the average intensity of all tumor sections.
Statistical analyses—Unless otherwise stated, a Student’s t-test or one-way ANOVA 
with Bonferroni’s post hoc test were used to test significance between populations. A 
significance threshold of p<0.05 was applied. Points and error bars plotted in graphs 
represent the mean ± s.e.m for 3 or more independent experiments..
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Impaired DICER expression in hypoxic human breast cancers
(a) DICER mRNA abundance in breast cancer patients from METABRIC stratified by 
DICER CNA and hypoxic fraction as determined with the Winter hypoxia metagene. P 
values obtained with Wilcoxon rank sum test. (b) Inverse correlation between DICER 
abundance and hypoxia score. P values obtained with Spearman’s correlation. (c) Kaplan-
Meier survival curves for DICER and hypoxia in pooled breast cancer dataset consisting of 
19 studies. (d) RNA was extracted from indicated breast cancer cell lines exposed to 0.2% 
O2 for 24 or 48 hours and subjected to quantitative RTPCR (qRT-PCR) analysis of DICER 
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with RPL13A as control (n≥3). Data represents mean ± s.e.m. P values obtained with one-
way ANOVA, Bonferroni’s post hoc test. (e) Representative Western blots were performed 
with antibody against DICER and anti-tubulin as control. (f) densitometric analysis of 
Western blots in e where the intensity of the DICER bands were normalized for tubulin 
signal (n=3). Error bars represent s.e.m. P values obtained with one-way ANOVA, 
Bonferroni’s post hoc test. *P<0.05, **P<0.01, ***P<0.001
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Figure 2. Epigenetic silencing of DICER promoter in response to hypoxia
(a) Total (Tot) and nascent (Nas) DICER mRNA expression during hypoxia in MCF7 and 
HMLER cell lines was determined using qRT-PCR with RPL13A as control (n=4). (b) 
Indicated breast cancer cell lines (n=3) or (c) HIF1α null MEFS (n=4) were exposed to 500 
μM iron chelator DFO, 250 μM antagonist CoCl2 or 500 μM DMOG for 24 hours. DICER 
mRNA expression was determined using qRT-PCR with RPL13A or 18S as control. (d) 
Western blot analysis of MCF7 cell extracts prepared after 24 hour exposure to 0.2% O2, 
500 μM DFO, 250 μM CoCl2 or 500 μM DMOG with antibodies specific for DICER, CA9, 
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and H3K27me3. Tubulin and H3 serve as respective loading controls. Representative blot 
(right) and densitometric analysis of Western blots from 4 independent experiments (left). 
(e) validation of the enrichment in H3K27me at the DICER promoter was done using ChIP 
analysis of H3K27me3 mark in combination with qRT-PCR analysis in MCF7 and HMLER 
cells during normoxia (N) or hypoxia (H). Fold-enrichment shown over control IgG (n=3). 
(f) enrichment of EZH2, KDM6A or KDM6B at the DICER promoter was done using ChIP 
analysis of each enzyme in combination with qRT-PCR analysis in MCF7 cells during 
normoxia (N) and hypoxia (H) (n=3). (g,h) qRT-PCR analysis of DICER expression with 
RPL13A as control in (g) MCF7 cells bearing shRNAs against KDM6A/B (n=3) or (h) 
treated with 10 μM KDM6A/B inhibitor GSK-J4 24hrs (n=3). (i) Representative blot (top) 
and quantification of global H3K27me3 (bottom) after GSK-J4 treatment in h. DICER 
mRNA expression in (j) MCF7 cells transiently transfected with siRNA directed against 
EZH2 during aerobic and hypoxic conditions (n=4) or (k) treated with 5 μM EZH2 inhibitor 
UNC1999 or GSK343 for 48hrs (n=3). (l) Representative Western blot (top) and 
quantification of global H3K27me3 levels (bottom) after EZH2 inhibition in k. Error bars 
represent s.e.m. P values obtained with Student’s t-test or one-way ANOVA, Bonferroni’s 
post hoc test. *P<0.05, **P<0.01, ***P<0.001
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Figure 3. Impaired miRNA processing in hypoxic cells
(a) MCF7 cells were transduced with lentiviral shRNA constructs directed at DICER. Cell 
extracts from MCF7 cells bearing empty vector pLKO.1, non-functional shDICER_G4 or 
functional shDICER_G6 were subjected to Western blot analysis using a DICER specific 
antibody. Tubulin served as loading control. (b) total RNA was extracted from MCF7 
pLKO.1 or shDICER_G6. miRNA levels were determined by Nanostring technology (n=3). 
(c) MCF7 cells exposed to hypoxia for 16 hours were used for total RNA isolation and 
subsequently subjected to deep-sequence analysis of miRNA content. Heat map of the 
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miR-200 family in MCF7 during hypoxia is shown. Bottom panel shows schematic 
representation of the genomic organization of the miR-200 family. (d) The ratio of mature 
miRNA to pri-miRNA for miR-200a, b and 429 in MCF7 cells after hypoxia, DICER 
knockdown (shRNA G6 and G8), KDM6 inhibitor GSK-J4 (10μM), EZH2 inhibitor 
UNC1999 (5μM) and DICER overexpression. Mature and pri-miRNA levels were 
determined by qRT-PCR. Similar experiments were performed in (e) HMLER and (f) 
SUM149 cells. (g,h) Processing of hypoxia inducible miR-210 was assessed as described in 
d for (g) MCF7 and (h) HMLER cells. Expression levels of mature and pri-miRNAs for the 
miR-210 family was determined by qRTPCR. N indicates normoxia, H indicates hypoxia. 
The data d-h represents mean ratios (n=3) ± s.e.m. P values obtained with Student’s t-test. 
*P<0.05, **P<0.01, ***P<0.001
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Figure 4. DICER repression promotes cancer stem cell associated phenotypes by reduced 
miR-200 expression during hypoxia
(a) HMLER cells were grown for 7 days under 1% O2. RNA was extracted and used to 
determine DICER mRNA levels by qRT-PCR analysis. Expression of epithelial and 
mesenchymal associated genes was assessed simultaneously. RPL13A served as control 
(n=3). (b) Similar analysis as in a was performed on HMLER cells transduced with 2 
independent shRNA constructs targeting DICER (n=3). (c) HMLER protein extracts were 
subjected to Western blot analysis of DICER, E-cadherin, Vimentin and eIF4E as loading 
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control. (d) Representative FACS analysis of HMLER cells using antibodies specific for 
CD44 and CD24. (e) Quantification of the percentage of cells with CD44highCD24low for 3 
independent experiments. (f) Sphere formation assay, number spheres formed per 500 cells 
plotted (n=3). (g) Representative image of whole tumor (top) and 25X region (bottom) of 
CD44 (green), EF5 (red) and DAPI (blue) staining in HMLER orthotopic xenograft. (h) 
Mean CD44 intensity in hypoxic (EF5 negative) versus non-hypoxic (EF5 positive) tumor 
regions of HMLER xenografts (n=8 mice). (i) Representative image of whole tumor (top) 
and 25X region (bottom) of H3K27me3 (green), EF5 (red) and DAPI (blue) staining in 
HMLER orthotopic xenograft. N indicates regions of tumor necrosis. Scale bar, 100 μm. 
Error bars represent s.e.m. P values obtained with Student’s t-test or one-way ANOVA, 
Bonferroni’s post hoc test. *P<0.05, **P<0.01, ***P<0.001
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Figure 5. Hypoxia stimulates cancer stem cell associated phenotypes in a miR-200b dependent 
manner
HMLER cells overexpressing miR-200b or GFP (n=3) grown for 7 days under 1% O2 or 
control conditions. (a,b) qRT-PCR analysis was performed to measure (a) mature miR200b 
levels, (b) DICER, ZEB1 and E-cadherin mRNA level where RPL13A served as control 
(n=3). (c) Representative FACS analysis using antibodies specific for CD44 and CD24. (d) 
Quantification of the percentage of cells with CD44highCD24low for 3 independent 
experiments. (e) Sphere formation assay, number spheres formed per 500 cells plotted (n=3). 
(f) Model of hypoxia mediated EMT and stemness. Error bars represent s.e.m. P values 
obtained with Student’s t-test. *P<0.05, **P<0.01, ***P<0.001
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